Author(s):
Sanjivani Rai, Abhishek Kanugo
Email(s):
abhi.kanugo09@gmail.com
DOI:
10.52711/0974-360X.2025.00278 
Address:
Sanjivani Rai1, Abhishek Kanugo1,2*
1Department of Pharmaceutics, SVKM NMIMS School of Pharmacy and Technology Management, Shirpur - 425405.
2Department of Pharmaceutical Quality Assurance, SVKM Institute of Pharmacy, Dhule, Maharashtra - 424001.
*Corresponding Author
Published In:
Volume - 18,
Issue - 5,
Year - 2025
ABSTRACT:
Apixaban is a novel oral anticoagulant widely recommended for the prevention and treatment of strokes and blood clots suffering from nonvalvular atrial fibrillation by suppressing factor Xa. Moreover, it is also useful in minimizing deep vein thrombosis and pulmonary embolism in patients after knee replacement surgery. The usefulness of Apixaban is circumscribed due to poor solubility and less bioavailability. The recent research aimed to develop an improved formulation of Apixaban by progressing the solubility and dissolution rate. The solubility estimation was carried out in numerous solubilizers and the highest solubility was reported in PEG 200. The compatibility was checked with FTIR, DSC, and crystalline nature with XRD. The optimization design involved Box-Behnken involving the concentration of MCC 102 (X1), Aerosil 200 (X2) and cross povidone (X3) as independent factors, whereas disintegration time (Y1) and dissolution release (Y2) were chosen as dependent factors. The ANOVA showed polynomial quadratic equations with p-values of 0.0028 and 0.0154 for the disintegration time and dissolution release correspondingly. The optimized batch F6 showed superior flowing characteristics and minimal quantity with maximum benefits. The tiniest disintegration time of 2.40 min and dissolution of 99.35 % was attained with batch F6. The cumulative drug released from this optimized batch was observed within 30 min. The marked improvement in the solubility and dissolution rate of Apixaban was achieved through the Liquisolid Compact Technique which facilitates greater bioavailability and therapeutic efficacy.
Cite this article:
Sanjivani Rai, Abhishek Kanugo. Integrated QbD Approach for the Development of Liquisolid Compact of Apixaban for Improvement of Solubility and Dissolution Rate. Research Journal of Pharmacy and Technology. 2025;18(5):1945-0. doi: 10.52711/0974-360X.2025.00278
Cite(Electronic):
Sanjivani Rai, Abhishek Kanugo. Integrated QbD Approach for the Development of Liquisolid Compact of Apixaban for Improvement of Solubility and Dissolution Rate. Research Journal of Pharmacy and Technology. 2025;18(5):1945-0. doi: 10.52711/0974-360X.2025.00278 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2025-18-5-1
REFERENCES:
1. Chin-Hon J, Davenport L, Huang J, Akerman M, Hindenburg A. Safety and efficacy of oral anticoagulants in extreme weights. Thromb Res. 2023; 231: 1–6.
2. Apixaban: Uses, Interactions, Mechanism of Action | DrugBank Online [Internet]. [cited 2023 Jul 16]; Available from: https://go.drugbank.com/drugs/DB06605
3. Kanugo A. Liquisolid-pellets technique: A recent technique for enhancing solubility and bioavailability of drugs. Int J Appl Pharm. 2020; 12(6): 34–40.
4. Bhavya E, Dhere MD. Liquisolid Compacts Technique of Poor Water Soluble Drugs: An Overview. Res J Pharm Technol. [Internet] 2021 [cited 2024 Jan 6];14(10):5569–72. Available from: https://rjptonline.org/AbstractView.aspx?PID=2021-14-10-88
5. Suthar C, Kanugo A. Liquisolid Compact Technique for the Enhancement of Solubility and Dissolution Rate of Ambrisentan: Quality by Design Approach. Indian J Pharm Sci. 2022; 84(6): 1417–28.
6. Sharma S, Kanugo A, Gaikwad J. Design and development of solid lipid nanoparticles of tazarotene for the treatment of psoriasis and acne: a quality by design approach. Mater Technol. [Internet] 2021 [cited 2021 Mar 19]; Available from: https://www.tandfonline.com/doi/abs/10.1080/10667857.2021.1873637
7. Kanugo A, Thanvi A. Neusilin US2 based Liquisolid Compact technique for the enhancement of solubility and dissolution rate of Olmesartan: Box-Behnken design approach. J Res Pharm. 2023; 27(1)(27(1)): 52–66.
8. Godbole M, Thangan A, Kanugo A. Improvement of solubility and dissolution rate of Repaglinide by Liquisolid Compact technique: QbD approach. J Res Pharm. 2022; 26(6): 1573–92.
9. Dholakiya A, Dudhat K, Patel J, Mori D. An integrated QbD based approach of SMEDDS and liquisolid compacts to simultaneously improve the solubility and processability of hydrochlorthiazide. J Drug Deliv Sci Technol. [Internet] 2021; 61(August 2020): 102162. Available from: https://doi.org/10.1016/j.jddst.2020.102162
10. Pathan LS, Modi CD, Gohel MC, Udhwani NH, Thakkar VT, Rana HB. Introducing novel hybridization technique for solubility enhancement of Bosentan formulation. Food Hydrocoll Heal. 2022; 2(July 2021): 100055.
11. Aparna A, Rubina Reichal C, Shobana M. Formulation and Characterization of Gastroretentive Drug Delivery System of Teneligliptin. Res J Pharm Technol. [Internet] 2023 [cited 2024 Jan 12]; 16(11): 5027–33. Available from: https://www.rjptonline.org/AbstractView.aspx?PID=2023-16-11-8
12. Jaipakdee N, Tabboon P, Limpongsa E. Application of a liquisolid technique to cannabis sativa extract compacts: Effect of liquid vehicles on the dissolution enhancement and stability of cannabinoids. Int J Pharm. 2022; 612: 121277.
13. Suram D, Narala A, Veerabrahma K. Development, characterization, comparative pharmacokinetic and pharmacodynamic studies of iloperidone solid SMEDDS and liquisolid compact. Drug Dev Ind Pharm. [Internet] 2020 [cited 2023 Oct 2];46(4):587–96. Available from: https://pubmed.ncbi.nlm.nih.gov/32162981/
14. Jaydip B, Dhaval M, Soniwala MM, Chavda J. Formulation and optimization of liquisolid compact for enhancing dissolution properties of efavirenz by using DoE approach. Saudi Pharm J. [Internet] 2020; 28(6): 737–45. Available from: https://doi.org/10.1016/j.jsps.2020.04.016
15. Kim HS, Kim CM, Jo AN, Kim JE. Studies on Preformulation and Formulation of JIN-001 Liquisolid Tablet with Enhanced Solubility. Pharmaceuticals. [Internet] 2022 [cited 2022 May 15];15(4):412. Available from: /pmc/articles/PMC9030333/
16. Thakkar HP, Vasava D, Patel AA, Dhande RD. Formulation and evaluation of liquisolid compacts of itraconazole to enhance its oral bioavailability. Ther Deliv. [Internet] 2020 [cited 2023 Oct 2]; 11(2): 83–96. Available from: https://pubmed.ncbi.nlm.nih.gov/31955698/
17. Shinde AJ, Walave PR, Tamboli FA, More HN. Formulation and Optimization of 5-Amino Salicylic acid Tablet for Colon Targeting. Res J Pharm Technol. [Internet] 2022 [cited 2024 Jan 6];15(10):4490–8. Available from: https://rjptonline.org/AbstractView.aspx?PID=2022-15-10-26
18. Devi S, Kumar S, Verma V, Kaushik D, Verma R, Bhatia M. Enhancement of ketoprofen dissolution rate by the liquisolid technique: optimization and in vitro and in vivo investigations. Drug Deliv Transl Res. 2022;12(11):2693–707.
19. Naik DCS, Bharathi A. Design and Evaluation of Fast Dissolving Tablets a Novel Natural Superdisintegrant is used in the Development of a BCS Class -II Drug. Res J Pharm Technol. [Internet] 2023 [cited 2024 Jan 12];16(4):1861–8. Available from: https://www.rjptonline.org/AbstractView.aspx?PID=2023-16-4-54
20. Pathak BK, Raghav M, Thakkar AR, Vyas BA, Shah PJ. Enhanced Oral Bioavailability of Etodolac by the Liquisolid Compact Technique: Optimisation, In-Vitro and In-Vivo Evaluation. Curr Drug Deliv. 2020; 18(4): 471–86.
21. Subramanian S, Monisha V. Investigating the use of Liquisolid Compact Technique for Pioglitazone HCl. Res J Pharm Technol. [Internet] 2022 [cited 2024 Jan 6];15(3):1013–7. Available from: https://rjptonline.org/AbstractView.aspx?PID=2022-15-3-12
22. Huynh MDT, Le MNT, Tran QT, Dang DK. Formulation and Stability of Orally Fast Disintegrating Tablets of Amlodipine besylate. Res J Pharm Technol. [Internet] 2023 [cited 2024 Jan 12]; 16(9): 4049–57. Available from: https://www.rjptonline.org/AbstractView.aspx?PID=2023-16-9-8.